Compare DexCom, Inc. (DXCM) vs Zoom Video Communications, Inc. (ZM) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Zoom Communications (ZM) trades at $93.03, up 2.07% today, with a bullish technical signal from moving averages and support near $91. The company reported Q1 2026 EPS of $1.55, beating expectations, and maintains strong profitability with a 77.4% gross margin. Recent news highlights AI product launches and the acquisition of Common Room, signaling growth initiatives. Cash flow from operations remains robust at $1.95 billion for 2025, though net cash flow was negative due to investing and financing activities.

The stock appears undervalued with a P/E of 13.64 relative to earnings growth, supported by a $118.79 analyst price target. Key risks include competitive pressure from Microsoft and Google, while the Anthropic stake offers upside potential. Institutional sentiment is mixed with 38.8% buy ratings, but insider selling and fluctuating cash flows warrant caution for near-term volatility.